Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus VEETIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus VEETIDS 250.
CYCLAPEN-W vs VEETIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
VEETIDS '250' is an oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
250 mg orally every 8 hours for 7-10 days
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
2-3 hours in adults with normal renal function; prolonged to 24-40 hours in anuria/end-stage renal disease, requiring dose adjustment.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Primarily renal (≥90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic